三友聯眾(300932.SZ):下游行業需求持續提升,推動公司原有項目訂單放量,營業收入實現同比顯著增長
格隆匯5月8日丨三友聯眾(300932.SZ)在投資者關係表示,公司2024年營收同比增長18.07%,主要驅動因素是什麼?答:一、市場需求擴張帶動存量業務增長:下游行業需求持續提升,推動公司原有項目訂單放量,營業收入實現同比顯著增長;二、新項目孵化貢獻增量:2023年重點佈局的開發類項目於報吿期內逐步轉化為需求落地(2023年培育期→2024年放量期),形成新的業績增長點;三、海外戰略成效顯現:通過前瞻性導入海外客户項目,加速全球化市場滲透,海外業務需求的擴容進一步增厚公司利潤空間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.